Pharma Deals Review, Vol 2005, No 60 (2005)

Font Size:  Small  Medium  Large

Genzyme Offers US$600 M for Bone Care

Business Review Editor

Abstract


Genzyme launched a US$600 M cash bid for the increasingly profitable speciality pharmaceutical company Bone care International. Pursuant to terms of the merger agreement, Genzyme will offer Bone care International shareholders US$33 per fully diluted share.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.